Combination drug fights lung cancer

Combination of TRAIL receptor targeted agents bortezomib can be used in lung cancer. The combination induces apoptosis in preclinical models of non-small cell lung cancer (NSCLC). This is evident from PhD research by Janet Stege House for NSCLC. Bortezomib is the intrinsic preference for TRAIL receptor 1 or TRAIL receptor 2-induced apoptosis by rhTRAIL in NSCLC cells change and apoptosis via bothSource URL: http://free-wallpapers-2.blogspot.com/2011/10/combination-drug-fights-lung-cancer.html
Visit Free Wallpapers | Wallpapers 2012 for daily updated images of art collection